SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Healthcare >

Interpace Diagnostics Group Inc. (IDXG)

Add IDXG Price Alert      Hide Sticky   Hide Intro
Moderator: beambe, ash111, MIC
Search This Board:
Last Post: 1/23/2017 7:16:35 AM - Followers: 69 - Board type: Free - Posts Today: 3


NASDAQ CM | IDXG (Common Stock)

Interpace Diagnostics Group, Inc., formerly PDI, Inc. is a molecular diagnostics development and commercialization company.

Corporate Headquarters

Interpace Diagnostics
Morris Corporate Center 1, Building A
300 Interpace Parkway
Parsippany, NJ 07054

Share Structure:

Authorized Shares: 100,000,000 shares

Outstanding shares: 18,162,671  shares (as of Aug 5, 2016) (hasn't changed since early 2016)

Current Book Value: $0.339 / share

Projected 2016 Revenue per share: on track for .61~.80/share (based on Q1/Q2 reports)

Short interest:


John P. Dugan: 4,869,878 common shares
other insiders: approx 2,672,149 shares collectively
total insiders: 7,542,027 shares

Institutional Ownership: 30.6% (5.5 mil shares)
largest institutional holder:
Heartland Advisors: 2,994,313

Publically traded float: 10,620,644 shares

if including institutional holders, Float = 5,120,644

Investment Highlights:

Interpace Diagnostics (IDX) was formerly part of PDI that had both IDX and Commercial Services (CSO) businesses. PDI was renamed Interpace Diagnostics Group after the sale of CSO in December 2015
•Focused on developing and marketing molecular based diagnostic tests in high value precision pre-cancerous test markets
•Three proprietary cancer molecular tests on the market in GI and Endocrine
•PancraGenTM–The new standard of pancreatic cyst diagnostics
•ThyGenXTMand ThyraMIRTM-Next-Gen sequencing oncogene panel and miRNAclassifier in combination to improve risk classification of Thyroid nodules
•Two state of the art CLIA-certified labs
•Additional pipeline tests under development including BarreGenTMfor Barrett’s Esophagus, an esophageal cancer risk classifier
•Addressable potential market opportunity of $2.7 billion with all four tests
•Revenue of approximately $10 million in 2015, supported by IDX sales forces
•Focus for 2016: Grow recently launched ThyGenX/ThyraMIRtests and expand PancraGenmarket penetration

Key Milestones:

AUGUST2014:Acquired ThyroidAssetsfrom Asuragen
OCTOBER2014: Acquired RedPathInc., GI assetsand CLIA lab
DECEMBER2014: Launched ThyGenX™NextGen Sequencing Thyroid Cancer Test
FEBRUARY2015: Published landmark study on PancraGen™in Endoscopy
APRIL2015: Launched ThyraMIR™microRNA Gene Expression Thyroid Cancer Test
MAY2015: Published the major clinical validation study in JCEM for combining ThyGenXand ThyraMIRin a single testing service
MAY2015: Published BarreGen™BASE study on Barrett’s Esophagus cancer risk progression in AJG
AUGUST2015: Covered lives for Interpace Diagnostics products exceeded 100 million for all tests combined
OCTOBER2015: Data presented at ACG demonstrate that PancraGen™can improve detection of malignant or highly aggressive pancreatic cysts over current guidelines criteria, and improve patient outcomes in real life management decisions
New data presented at ATA further validates the power of combination testing by ThyGenX™and ThyraMIR™, improving the preoperative diagnosis of thyroid nodules with indeterminate cytology
DECEMBER2015: PDI transformed into Interpace Diagnostics Group through the sale of its CSO business to focus exclusively on molecular diagnostics

High Value Molecular Pre-Cancerous Test Market:


Management Team:

Jack Stover, Interim President and CEO

Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (“Zebec”) since April 2014.  Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013.  Mr. Stover has been a Director and Chairman of the Audit Committee of PDI, Inc., a public company since 2005. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins.  Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011.

From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange.  Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries.  Prior to that, Mr. Stover was executive vice president and director of a proprietary women’s pharmaceutical company, Gynetics, Inc. (“Gynetics”), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company.  For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the lifesciences industry division.  Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.

Greg Richard, SVP Commercial Services
Greg Richard, Sr. Vice President of PDI, Inc. and SVP of Commercial Services at Interpace Diagnostics, has been in the healthcare business for over 25 years in various industries including managed care, biotech pharmaceuticals, CRO services, and diagnostics. He started his career in sales at Aetna and moved to Genentech as the Director of Managed Care. He transitioned in to the diagnostics industry as the Vice President of Managed Care for Quest Diagnostics and served in this role for 8 years. Greg also led the international clinical trials sales team while at Quest. Following his tenure at Quest, Greg worked for several privately held companies including CRO’s, molecular diagnostics, and anatomic pathology services providers. He also served as the Sr. Vice President of Sales for the Northeast Division of LabCorp. Greg is a certified Six Sigma Green Belt and frequent speaker at healthcare industry conferences such as the G2 Lab Institute and the NextGen Dx Summit.

Syd Finkelstein, Chief Scientific Officer
Dr. Finkelstein is a board certified pathologist specializing in gastrointestinal pathology with extensive experience in molecular diagnostics. He is the Adjunct Professor of Pathology, Drexel University on the faculty of Allegheny General Hospital, Pittsburgh, PA. He serves as Adjunct Professor at Temple University.  He is the founder of RedPath Integrated Pathology, which was acquired by Interpace Diagnostics in 2014.  In this position, Dr. Finkelstein is applying clinical translational research of molecular genetic discoveries to standard surgical pathology practice a goal to which he has dedicated his entire career.   He spent 20 years as a practicing academic surgical pathologist, holding appointments as associate and then full professor at the University of Pittsburgh and at Hahnemann University in Philadelphia. In 1990, he began work on the development of Topographic Genotyping, his patented technology for enhancing polymerase chain reaction amplifiability of minute, microdissected, fixative treated tissue samples. Dr. Finkelstein is a nationally recognized expert in both Gastrointestinal Pathology and Solid Tissue Molecular Pathology.

James E. Early, Interim CFO 

Mr. Early, age 62, previously served as the Interim and subsequently permanent Chief Financial Officer of AbGenomics International Inc., a clinical stage drug development company with a product pipeline in immunology and oncology, from September 2015 to July 2016. Mr. Early also previously served as the Chief Financial Officer of Zebec Therapeutics, LLC from October 2014 to September 2015. In addition, Mr. Early has provided interim chief financial officer and business development services for pharmaceutical, life science and other similar companies as a sole proprietor from August 2009 to December 2013 and through Early Financial Consulting, LLC from January 2014 to the present. Mr. Early is a Certified Public Accountant and has an MBA in Finance and Accounting.
Summary of Early's CFO services:

  • Strategic Planning
    Deal Procurement and Contract Negotiations
    Capitalization and Long-Term Financing
    Private Equity Modeling
    Insurance/Risk Management
    IRC 409A and FAS 123R Share Payment/Stock Option Valuation Support
    Treasury Management
    Internal Audits

Current Marketed Products:

BarreGen is a Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

Key Points:

  • While only about 0.5% of Barrett's esophagus patients will develop esophageal cancer, the 5-year survival rate of esophageal cancer ranges from 4% to 40%.

    BarreGen utilizes an assay that assesses loss of heterozygosity and genetic mutations of multiple tumor-suppressor genes.

    A longitudinal study shows the BarreGen test had an overall accuracy of 95% in identifying patients who progressed to cancer from those who did not.

PancraGEN® is a unique, DNA-based pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate, according to clinical studies, enabling effective risk stratification of patients.  Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.

Long-term follow-up outcomes data of patients (up to 8 years) from the National Pancreatic Cyst Registry supports PancraGEN’s ability to help accurately inform surgery and surveillance decisions of patients.

In a study of the National Pancreatic Cyst Registry, PancraGEN’s recommendation of surveillance was correct in 97% of patients. In fact, PancraGEN diagnoses were more beneficial to overall patient outcomes than sole reliance on International Consensus Guidelines (ICG) criteria.

PancraGEN has been performed on over 25,000 patients with pancreatic cysts, representing a full spectrum of pancreatic cyst patients with diverse clinical and molecular findings.

Medical Publications proving benefits of PancraGen:

ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer.  ThyGenX® and ThyraMIR™ combination testing helps to better assess the risk of thyroid nodules being either benign or malignant—and helps reduce unnecessary surgeries.
ThyGenX® is a highly specific oncogene (mutational) panel that assesses the most common genetic alterations across 8 genes associated with papillary carcinoma and follicular carcinoma.
ThyraMIR™ is the first and only miRNA gene expression classifier, and is based on evaluation of expression of 10 miRNAs.

Interpace Diagnostics' ThyGenX™ Thyroid Oncogene Panel molecular diagnostic test is used to improve surgical decision-making for patients with thyroid nodules when standard cytopathology does not provide a clear diagnosis of thyroid cancer. ThyGenX assists physicians in distinguishing between benign and malignant indeterminate thyroid nodules by utilizing state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid malignancies. The ThyGenX panel design is based on the miRInform® test, whose high predictive value has been validated in a recent prospective clinical study involving over 600 patients. Interpace Diagnostics acquired the miRInform test from Asuragen in 2014, and has now enhanced it by upgrading to a NGS platform which provides greater genomic insights and increased panel content.

Better than the competition:

"RE: our Thyroid products, customers continue to be receptive to our combined ThyGenX/ThyraMir assay and we are viewed positively vs. the other products in the market, including Afirma, ThyroSeq2, and Rosetta.  We will also be launching enhancements to our Thyroid offering in the next few weeks." Greg Richard (email 9-21-16)


AccuCEA is our highly accurate CEA method designed specifically for pancreatic cyst fluids and is especially convenient when used with PancraGEN.  Interpace currently performs over 6,000 AccuCEA tests per year for their customers.  CEA is a blood fluid chemistry test that is commonly done as part of an initial screening performed on patients suspected of having pancreatic and other types of cancer.

-The only CEA assay validated for use on small volumes (200uL) of cyst fluid.
-Delivers accurate CEA measurements on pancreatic cyst fluids
-Offers physicians more options – reserve cyst fluid for other diagnostic tests
-Results reported within 1-3 business days

New Version of AccuCEA™ Called "Insights" Provides Physicians Access to 15,000 Patient Database:

The new AccuCEA Insights service provides physicians for whom the Company has already provided first line testing, with additional information on how those results compare to those of other patients in the Company's proprietary database of over 15,000 patients, thus reporting incremental and valuable information on the patient's potential molecular profile and overall risk for developing pancreatic cancer. When the report is delivered to the ordering physician, they have an opportunity to speak with one of the Company's expert molecular pathologists and discuss the potential benefits of conducting a full, molecular pathology review using PancraGen®, the Company's fully integrated product that considers all the results from first line testing, imaging, cytology, and molecular testing and stratifies the patient in one of 4 risk categories.

Upcoming Events/Presentations:

86th Annual Meeting of the American Thyroid Association (ATA) in Denver, Colorado

The first of the two posters entitled "Molecular Analysis of Thyroid Malignancy Using Cytology Smears by Combined THYGENX™ and THYRAMIR™ testing: A Prospective Study" highlights the clinical performance of the combined ThyGenX + ThyraMIR tests when carried out on Fine Needle Aspirate (FNA) material smeared on cytology slides.  

The second poster entitled "The Majority of Non-Diagnostic (Insufficient) Thyroid Nodule Cytology Samples Can Effectively Undergo Molecular (Combined Mutational and MicroRNA Classifier) Analysis Using a Needle Aspiration Approach" demonstrates that Interpace's scientists were able to perform molecular analysis in cases where cytology results were insufficient. 

Set for presentation of posters 50 and 51 on Sept 23:

ACG 2016 Annual Scientific Meeting Oct 14-19 in Las Vegas

"DNA Analysis of Pancreatic Cystic Lesions Has Value in Assessing Risk of Future Malignancy"
Oct 19, presented by:

James J. Farrell, MD, Sara Jackson, PhD, Nicole Toney, MPH,
Tamas Gonda, MD, Yale University School of Medicine, New
Haven, CT, Interpace Diagnostics Corporation, Pittsburgh, PA,
New York-Presbyterian/Columbia University Medical Center, New
York, NY

"We are attending the ACG mtg. in Oct. in Las Vegas, where data on our PancraGen test is being presented in a podium presentation by Dr. James Farrell of Yale. " Greg Richard (email 9-21-16)

Preliminary Program (refer to page 41 of pdf)

Recent News:

09/12/16 Interpace Diagnostics Invited to Present Data at Upcoming American Thyroid Association (ATA) Annual Meeting
08/24/16 Interpace Diagnostics Launches New Product for Pancreatic Cancer Testing
08/16/16 Interpace Diagnostics Reports Record Revenue and Cash Collections for the 2016 Second Quarter
08/04/16 Interpace Diagnostics Announces New York State Approval of Thyroid Test
07/06/16 Interpace Diagnostics Announces Long-Term Outcomes Data for Cohort of 492 Patients
06/01/16 Interpace Diagnostics Announces New Health Economic Data Publications
05/23/16 Interpace Diagnostics Presents New Clinical Utility Data at Digestive Disease Week
05/12/16 Interpace Diagnostics Reports 2016 First Quarter Financial Results and Operational Performance
04/25/16 Interpace Diagnostics Announces Reimbursement Approval By Major National Managed Care Organization
04/18/16 Interpace Diagnostics Announces New Coding by Novitas Solutions for PancraGen™
04/07/16 Interpace Diagnostics Reports Record Cash Collections During March
04/05/16 Interpace Diagnostics Announces Agreement With Galaxy Health Network To Cover All Products
03/30/16 Interpace Diagnostics Group Reports 2015 Financial Results and Recent Accomplishments
03/23/16 Interpace Diagnostics Implements Broad Based Efficiencies and Cost-Cutting Measures Resulting in Significant 2016 Savings
03/01/16 Interpace Diagnostics Announces Agreement with America's Choice Provider Network to Cover All of the Company's Molecular Tests for Thyroid and Pancreatic Cancer
02/17/16 Interpace Diagnostics Receives Medicare Coverage For Its ThyraMIR™ Micro RNA Gene Expression Classifer
01/28/16 PancraGen® Clinical Utility Study Published in Diagnostic Pathology
01/20/16 Interpace Diagnostics Announces New Medicare Local Coverage Determination for Molecular Testing of Pancreatic Cysts
01/12/16 Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IDXG News: Interpace Diagnostics Announces $4.0 Million Registered Direct Offering of Common Stock 01/20/2017 12:30:00 PM
IDXG News: Current Report Filing (8-k) 01/20/2017 12:01:43 PM
IDXG News: Interpace Diagnostics Announces New Partnership with Israeli Specialty Services Provider 01/20/2017 08:00:00 AM
IDXG News: Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement 01/17/2017 08:00:00 AM
IDXG News: Amended Statement of Ownership (sc 13g/a) 01/10/2017 10:30:38 AM
#1676   Keep in mind that they can't claim to Renegades17 01/23/17 07:32:07 AM
#1675   I agree with you. I will try Renegades17 01/23/17 07:16:35 AM
#1674   Today we salute you, Mr. Restroom Toilet Paper Getitgogone 01/23/17 02:03:43 AM
#1673   it's toxic financing at it's finest. This beavissolid 01/22/17 11:17:06 PM
#1672   Great post Renegades17,seems you and I had a Getitgogone 01/22/17 08:37:04 PM
#1671   Stock is about to gap down and filled beavissolid 01/22/17 06:54:17 PM
#1670   Trailing stop orders work great for stocks that recinvestor 01/22/17 06:29:06 PM
#1669   I wish the company would put out An danlevitan 01/22/17 06:19:38 PM
#1668   Great post/info, thx. colmar 01/22/17 05:31:41 PM
#1667   Summary of the recent offerings Renegades17 01/22/17 04:12:57 PM
#1666   With recent offerings what is the amount of danlevitan 01/22/17 02:28:14 PM
#1665   I'm expecting a pr Monday or Tuesday....lately company danlevitan 01/22/17 02:12:50 PM
#1664   This stinker will drop to a dollar ...pump danlevitan 01/22/17 04:57:47 AM
#1663   Dropping from up 66% to down 6% in beavissolid 01/21/17 09:58:15 PM
#1662 weekend too....can't see this going lower.. danlevitan 01/21/17 02:52:23 PM
#1661   If they want to rebuild their credibility they Getitgogone 01/21/17 02:35:03 PM
#1660   What is the float on can this danlevitan 01/21/17 02:20:47 PM
#1659   What is the float on can this danlevitan 01/21/17 02:20:35 PM
#1658   What is the float on can this danlevitan 01/21/17 02:20:29 PM
#1657   We need a positive pr without dillution danlevitan 01/21/17 02:05:00 PM
#1656   RSI is 43.8; hasn't been that low since colmar 01/21/17 01:35:07 PM
#1655   RSI on the daily is 44, weekly vintagesake 01/21/17 01:12:52 PM
#1654 vintagesake 01/21/17 12:56:28 PM
#1653   Plenty of room to grow here folks investors ozzz 01/21/17 12:43:44 PM
#1652   agree we're oversold; RSI says so. Monday could colmar 01/21/17 10:57:57 AM
#1651   What about next week ...way oversold...price way below danlevitan 01/21/17 10:51:34 AM
#1650   dilution needs to end fairly soon and price colmar 01/21/17 09:28:50 AM
#1649   I've wanted to do some flipping and have, Getitgogone 01/21/17 06:19:38 AM
#1648   I bought at 6 worder when we will danlevitan 01/21/17 05:49:57 AM
#1647   Won't get any argument from me... seems the Getitgogone 01/21/17 05:33:31 AM
#1646   Still low float and small many of danlevitan 01/21/17 05:18:26 AM
#1645   Is it possible the offering scared retail created danlevitan 01/21/17 05:08:15 AM
#1644   Alot of shorting going on here possible squeeze....seems oversold... danlevitan 01/21/17 04:55:35 AM
#1643   Gobble Gobble Getitgogone 01/21/17 04:34:44 AM
#1642   After the RS and the offering what is danlevitan 01/21/17 04:08:16 AM
#1641   With the offering how many shares are out there..... danlevitan 01/21/17 04:00:15 AM
#1640   With the offering how many shares are out there..... danlevitan 01/21/17 04:00:13 AM
#1639   I get what you're saying but it's obviously rpablo23 01/20/17 05:57:58 PM
#1638   I get it .... I just think at Getitgogone 01/20/17 05:33:44 PM
#1637   Short term looks like the gap at 2.50 vintagesake 01/20/17 05:11:19 PM
#1636   I think all of you that missed or Jerry04 01/20/17 04:13:55 PM
#1635   Good points for the most part imo. colmar 01/20/17 03:57:38 PM
#1634   I have to disagree with those that are Getitgogone 01/20/17 03:55:19 PM
#1633   I love these low floaters!! :) mayvid 01/20/17 01:57:32 PM
#1632   The rub is I don't think retail can vintagesake 01/20/17 01:20:34 PM
#1631   I agree. It's the same pattern every rpablo23 01/20/17 12:59:20 PM
#1630   I was away from the computer... or else outkast2 01/20/17 12:55:31 PM
#1629   The Company intends to use the aggregate net rpablo23 01/20/17 12:45:34 PM
#1628   It's called diluting jonsmile 01/20/17 12:45:21 PM
#1626   Who said they couldn't issue any more shares? rpablo23 01/20/17 12:32:49 PM